Sanofi's R&D head exits, with AI biotech Xaira's exec stepping in
Sanofi loses its R&D head to AI biotech Xaira Therapeutics, which is contributing its executive to the pharma giant.
Xaira Therapeutics
Private
AI-driven drug discovery company applying generative models and machine learning to small molecule and biologics design.
Company Info
Sector:AI / Machine Learning
Headquarters:South San Francisco, California, USA
Founded:2023
Website:www.xaira.com/
Funding Round:Series A
Total Funding:$1B+ (initial funding)
Funding & Investor Relations
Notable Investors
- ARCH Venture Partners
- Foresite Capital
- Lux Capital
- Sequoia Capital
Upcoming Milestones & Key Dates
2026 H2
Regulatory filing
First AI-designed candidate IND filing
2027 H1
Financing event
Additional Series funding
Clinical Development Pipeline
Undisclosed
Target: AI-designedUndisclosed
Target: AI-designedUndisclosed
Target: AI-designedRecent News
Leadership Team
Marc Tessier-Lavigne
Co-founder, Chairman and Chief Executive Officer